Today before the opening
bell, an interview with president and Chief Executive Officer Dr. Kaushik J.
Dave, a 25-year veteran with extensive biotech and pharmaceutical experience,
was released. The full audio interview is available at the following link: http://ATNM.MissionIR.com/interview.html.
Actinium is a biotech
company leveraging modern science and its proprietary platform to develop and
commercialize groundbreaking therapies for treatment in different types of
cancer that currently do not have any approved treatment.
Iomab-B is the company’s
lead program for bone marrow conditioning in patients with acute myeloid
leukemia (AML) who do not have any curative treatment options. Iomab-B is
poised to start a pivotal phase 3 study, backed by significant data from five
completed phase 1 and phase 2 clinical trials.
“This program has the
potential to disrupt the field of bone marrow transplant, and as a consequence,
has attracted a significant amount of interest from the medical community,” Dr.
Dave stated in the interview.
Actinium’s pipeline also
includes Actimab-A, currently in phase 1/phase 2 clinical studies as a primary
induction treatment of AML. The company’s business model is to leverage its
expertise and strong partnerships with leading cancer institutions to further
the development of these drug candidates.
Dr. Dave detailed his
education and extensive background in the pharmaceutical industry and drug
development, noting that his interest in joining Actinium stemmed from
recognizing the company’s “significant unrealized potential for growth.” Dr.
Dave also briefly touched on the blended expertise of the rest of Actinium’s
leadership and board of directors.
“These folks, all of them,
bring complementary skills… all of which make our team well-equipped to face
challenges of a rapidly ascending biotech company,” he stated.
In 2013, Actinium achieved
several important milestones, as explained by Dr. Dave in the interview, which
have positioned the company to reach several key objectives in 2014, including:
• Iomab-B poised to start
phase 3
• Interim phase 2 results
for Actimab-A
• Uplist to Nasdaq or NYSE
exchange
• Obtaining additional
analyst coverage
• Establish strategic
collaborations
Wrapping up the interview,
Dr. Dave explained Actinium position in the biotech industry, how it is raising
awareness in the investment community, and the company’s recent private
placement of approximately $6.6 million in gross proceeds, which is allocated
toward achieving the company goals for the year.
For more information, visit
www.ActiniumPharmaceuticals.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
